Euro Pacific Asset Management LLC Buys 25,273 Shares of Novo Nordisk A/S $NVO

Euro Pacific Asset Management LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 28.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,430 shares of the company’s stock after purchasing an additional 25,273 shares during the period. Novo Nordisk A/S accounts for about 1.3% of Euro Pacific Asset Management LLC’s portfolio, making the stock its 26th biggest holding. Euro Pacific Asset Management LLC’s holdings in Novo Nordisk A/S were worth $7,967,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of NVO. Copeland Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. bought a new stake in Novo Nordisk A/S in the 1st quarter valued at about $27,000. Stone House Investment Management LLC acquired a new position in shares of Novo Nordisk A/S during the first quarter valued at about $30,000. Disciplina Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 297 shares in the last quarter. Finally, Spirit of America Management Corp NY purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $35,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. HSBC set a $70.00 target price on Novo Nordisk A/S in a research note on Wednesday. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Finally, UBS Group downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $77.50.

Novo Nordisk A/S Trading Up 1.6%

NYSE:NVO opened at $59.68 on Monday. The business has a fifty day moving average price of $54.92 and a 200-day moving average price of $63.63. The firm has a market capitalization of $266.45 billion, a price-to-earnings ratio of 16.39, a price-to-earnings-growth ratio of 2.63 and a beta of 0.68. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $120.56.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s payout ratio is 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.